Prognostic significance of the lymphocyte-to-monocyte ratio in patients with malignant pleural mesothelioma

Lung Cancer. 2015 Oct;90(1):111-7. doi: 10.1016/j.lungcan.2015.07.014. Epub 2015 Jul 30.

Abstract

Objectives: Chronic inflammation plays a key role in the pathogenesis of malignant pleural mesothelioma (MPM) as a result of asbestos exposure. Several inflammation-based prognostic scores including the lymphocyte-to-monocyte ratio (LMR), Glasgow Prognostic Score (GPS), neutrophil-to-lymphocyte ratio (NLR), and platelet-to-lymphocyte ratio (PLR) reportedly predict survival in many malignancies, while the role of LMR in MPM remains unclear. The aim of this study was to evaluate the clinical value of LMR and to compare the prognostic value of these inflammation-based scores in predicting overall survival (OS) in MPM.

Materials and methods: One hundred and fifty patients with histologically proven MPM were included in this retrospective study. Kaplan-Meier curves and multivariate Cox-regression analyses were calculated for OS. The area under the receiver operating characteristics curve (AUC) was calculated to compare the discriminatory ability of each scoring system.

Results: An elevated LMR was significantly associated with prolonged OS. Patients with LMR <2.74 had significantly poor survival compared with LMR ≥2.74 (median, 5.0 versus 14.0 months; p=0.000). The LMR consistently had a higher AUC value at 6 months (0.722), 12 months (0.712), and 24 months (0.670), compared with other scores. Multivariate analysis showed that the LMR was independently associated with OS.

Conclusions: The LMR is an independent prognostic marker for OS in patients with MPM and is superior to other inflammation-based prognostic scores with respect to prognostic ability.

Keywords: Asbestos; Lymphocyte-to-monocyte ratio; Malignant pleural mesothelioma; Prognostic score.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Asbestos / adverse effects
  • Biomarkers, Tumor / analysis
  • Female
  • Humans
  • Inflammation / blood
  • Inflammation / pathology
  • Lung Neoplasms / blood*
  • Lung Neoplasms / pathology*
  • Lung Neoplasms / therapy
  • Lymphocytes / pathology*
  • Male
  • Mesothelioma / blood*
  • Mesothelioma / pathology*
  • Mesothelioma / therapy
  • Mesothelioma, Malignant
  • Middle Aged
  • Monocytes / pathology*
  • Neutrophils / pathology
  • Prognosis
  • ROC Curve
  • Retrospective Studies

Substances

  • Biomarkers, Tumor
  • Asbestos